I agree, but whether or not the combo-trial happens, it the PR calls international attention to Leronlimab's positive outcomes and zero SAE history. The contrast between Rem and Leronlimab will be that much sharper should the trial go forward. I hope we don't have to wait for it to report data before FDA grants compassionate use (at a minimum), for pete's sake.

One could argue the market is starting to get the message, watching GILD SP.